Source:http://linkedlifedata.com/resource/pubmed/id/21034246
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0004927,
umls-concept:C0006041,
umls-concept:C0013203,
umls-concept:C0015737,
umls-concept:C0019682,
umls-concept:C0019699,
umls-concept:C0033052,
umls-concept:C0033105,
umls-concept:C0038951,
umls-concept:C0043210,
umls-concept:C0205547,
umls-concept:C0242781,
umls-concept:C0449450,
umls-concept:C0950580,
umls-concept:C1521797
|
pubmed:issue |
4
|
pubmed:dateCreated |
2011-4-4
|
pubmed:abstractText |
The emergence and spread of transmitted drug resistance (TDR) poses a major threat to the success of the rapidly expanding antiretroviral treatment (ART) programs in resource-limited countries. The World Health Organization recommends the use of the HIV Drug Resistance Threshold Survey (HIVDR-TS) as an affordable means to monitor the presence of TDR in these settings. We report our experiences and results of the 2007 HIVDR-TS in Botswana, a country with one of the longest-existing national public ART programs in Africa. The HIVDR-TS and HIV-1 incidence testing were performed in the two largest national sites as part of the 2007 antenatal Botswana Sentinel Survey. The HIVDR-TS showed no significant drug resistance mutations (TDR less than 5%) in one site. TDR prevalence, however, could not be ascertained at the second site due to low sample size. The agreement between HIVDR-TS eligibility criteria and laboratory-based methodologies (i.e., BED-CEIA and LS-EIA) in identifying recently HIV-1 infected adults was poor. Five years following the establishment of Botswana's public ART program, the prevalence of TDR remains low. The HIVDR-TS methodology has limitations for low-density populations as in Botswana, where the majority of antenatal sites are too small to recruit sufficient numbers of patients. In addition, the eligibility criteria (age <25 years and parity (first pregnancy)) of the HIVDR-TS performed poorly in identifying recent HIV-1 infections in Botswana. An alternative sampling strategy should be considered for the surveillance of HIVDR in Botswana and similar geographic settings.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1931-8405
|
pubmed:author |
pubmed-author:AndersonMarina GMG,
pubmed-author:BileEbi-CelestinEC,
pubmed-author:BodikaStephane MSM,
pubmed-author:BussmannHermannH,
pubmed-author:EsserGG,
pubmed-author:LehotzkyErica AnnEA,
pubmed-author:MakhemaMoeketsi JMJ,
pubmed-author:MarlinkRichard GRG,
pubmed-author:MineMadisaM,
pubmed-author:MlotshwaBusisiweB,
pubmed-author:MmelesiMphoM,
pubmed-author:MoyoSikhulileS,
pubmed-author:MphoyakgosiKerengK,
pubmed-author:NovitskyVladimirV,
pubmed-author:RoelsThierry HTH,
pubmed-author:SeiponeKhumoK,
pubmed-author:TaffaNegussieN,
pubmed-author:WesterC WilliamCW,
pubmed-author:YangChunfuC,
pubmed-author:de la Hoz GomezFlorindoF
|
pubmed:issnType |
Electronic
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
365-72
|
pubmed:meshHeading |
pubmed-meshheading:21034246-Adult,
pubmed-meshheading:21034246-Anti-HIV Agents,
pubmed-meshheading:21034246-Botswana,
pubmed-meshheading:21034246-Drug Resistance, Viral,
pubmed-meshheading:21034246-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:21034246-Female,
pubmed-meshheading:21034246-Genotype,
pubmed-meshheading:21034246-HIV Infections,
pubmed-meshheading:21034246-HIV-1,
pubmed-meshheading:21034246-Humans,
pubmed-meshheading:21034246-Microbial Sensitivity Tests,
pubmed-meshheading:21034246-Molecular Typing,
pubmed-meshheading:21034246-Pregnancy,
pubmed-meshheading:21034246-Prevalence,
pubmed-meshheading:21034246-RNA, Viral,
pubmed-meshheading:21034246-Sequence Analysis, DNA
|
pubmed:year |
2011
|
pubmed:articleTitle |
Prevalence of transmitted HIV drug resistance in Botswana: lessons learned from the HIVDR-Threshold Survey conducted among women presenting for routine antenatal care as part of the 2007 national sentinel survey.
|
pubmed:affiliation |
Botswana-Harvard AIDS Institute (BHP) , Gaborone, Botswana.
|
pubmed:publicationType |
Journal Article
|